Lyra Therapeutics, Inc.

NASDAQ (USD): Lyra Therapeutics, Inc. (LYRA)

Last Price

0.383

Today's Change

+0.015 (4.07%)

Day's Change

0.358 - 0.419

Trading Volume

5,698,693

Overview

Market Cap

23 Million

Shares Outstanding

60 Million

Avg Volume

2,907,447

Avg Price (50 Days)

4.49

Avg Price (200 Days)

4.20

PE Ratio

-0.33

EPS

-1.17

Earnings Announcement

06-Aug-2024

Previous Close

0.37

Open

0.37

Day's Range

0.3576 - 0.4185

Year Range

0.347 - 6.79

Trading Volume

5,714,668

Price Change Highlight

1 Day Change

4.19%

5 Day Change

5.42%

1 Month Change

-92.62%

3 Month Change

-92.34%

6 Month Change

-86.88%

Ytd Change

-92.63%

1 Year Change

-85.76%

3 Year Change

-94.64%

5 Year Change

-97.94%

10 Year Change

-97.94%

Max Change

-97.94%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment